UPDATE: Piper Jaffray Downgrades IntegraMed America to Neutral on Acquisition by Sagard Capital

Loading...
Loading...
Piper Jaffray lowers its rating on IntegraMed America
INMD
from Overweight to Neutral and adjusts its price target from $14 to $14.05 (the offer price). Piper Jaffray notes, "IntegraMed announced it has entered into an agreement to be acquired by the investment fund Sagard Capital Partners for $14.05/share or an equity value of $169.5 MM. The acquisition values the company at ~6.4x our FY12 estimated EV/EBITDA, while the equity value take-out offer is 7.75x FY12E EBITDA, which we believe is a fair valuation for the company. Since ~30% of the outstanding shares have agreed to this transaction (INMD's largest shareholder and Sagard Capital), we think it is unlikely there will be a competing offer." INMD closed at $13.68 on Monday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetIntraday UpdateAnalyst RatingsPiper Jaffray
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...